NCT06859710 THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy
| NCT ID | NCT06859710 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University of California, Los Angeles |
| Condition | Abuse, Drug |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-11-05 |
| Primary Completion | 2027-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 30 participants in total. It began in 2025-11-05 with a primary completion date of 2027-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to assess the impact of CBD on the effects of THC.
Eligibility Criteria
Inclusion Criteria: * Male or non-pregnant and non-lactating females aged 21-55 years * Report cannabis use 1-7 days per week over the month prior to screening * Not currently seeking treatment for their cannabis use * History of inhaled cannabis use * Have a Body Mass Index from 18.5 - 34 kg/m2 * Able to perform all study procedures * Must be using a contraceptive (hormonal or barrier methods) Exclusion Criteria: * Meeting DSM-V criteria for severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine, mild or moderate CUD * Evidence of severe psychiatric illness (e.g. mood or anxiety disorder with functional impairment or suicide risk, schizophrenia) judged by the study physician (and PI) to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent. * Report using other illicit drugs in the prior 4 weeks * Current pain * Pregnancy * Currently enrolled in another research protocol * Not using a contraceptive method (hormonal or barrier methods) * Insensitivity to the cold water stimulus of the Cold Pressor Test * Any disorders that might make cannabis administration hazardous as determined by evaluation physician after review of all medical assessments along with medical history. * Not able to speak and read English
Contact & Investigator
Ziva Cooper, PhD
PRINCIPAL INVESTIGATOR
University of California, Los Angeles
Frequently Asked Questions
Who can join the NCT06859710 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 55 Years, studying Abuse, Drug. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06859710 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06859710 currently recruiting?
Yes, NCT06859710 is actively recruiting participants. Contact the research team at zcooper@mednet.ucla.edu for enrollment information.
Where is the NCT06859710 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT06859710 clinical trial?
NCT06859710 is sponsored by University of California, Los Angeles. The principal investigator is Ziva Cooper, PhD at University of California, Los Angeles. The trial plans to enroll 30 participants.